Amani Therapeutics

Amani TherapeuticsAmani Therapeutics
AT

Amani Therapeutics

Developing highly efficacious, safer medicines.

Active
Rate

About

Amani Therapeutics is a biotechnology company focused on developing highly efficacious, safer medicines for people living with various conditions. The company was founded with backing from RTW Investments and has in-licensed a Phase 3-ready novel chemical entity (NCE) from AstraZeneca as part of its lead program, AM-01.
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Amani Therapeutics do?

Amani Therapeutics is a biotechnology company focused on developing highly efficacious, safer medicines for people living with various conditions. The company was founded with backing from RTW Investments and has in-licensed a Phase 3-ready novel chemical entity (NCE) from AstraZeneca as part of its lead program, AM-01.

How much funding has Amani Therapeutics raised?

Amani Therapeutics has raised a total of $25M in funding. The most recent round on record is Series A.

Where is Amani Therapeutics headquartered?

Amani Therapeutics is headquartered in New York, USA.

What industry does Amani Therapeutics operate in?

Amani Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare.

What is Amani Therapeutics's revenue?

StartupHub estimates Amani Therapeutics's annual revenue at $3.2M (range $813K to $10.5M, 37% confidence), based on comparable companies in the sector.

What is Amani Therapeutics's valuation?

StartupHub estimates Amani Therapeutics's effective valuation at $101.5M (range $62.5M to $150.0M, 24% confidence), based on comparable companies in the sector.